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1. Introduction
The gold standard for treatment of advanced heart valve disease is surgical heart valve re‐
placement. None of the currently available mechanical and bioprosthetic heart valve substi‐
tutes resembles normal heart valve function. While mechanical heart valves offer excellent
durability, they require life-long anticoagulation to control thromboembolism, which inher‐
ently leads to an increased risk of hemorrhage complications. Bioprosthetic valves on the other
hand, retain a more physiological blood flow pattern, but these valves are prone to calcifica‐
tion and structural deterioration, limiting their lifespan. For both types of replacement valves,
the main limitation is that they are non-living prostheses, incapable of adapting to changes in
the hemodynamic environment. It was shown that a living autograft implanted in the aortic
position (the Ross procedure) improves long-term clinical outcome compared to a non-living
homograft [1]. This illustrates the importance of the regulatory and adaptive properties of a
living valve substitute. Tissue engineered aortic valves can provide such an autologous, viable
valve with the potential to grow, adapt, and regenerate within the hemodynamic environ‐
ment. Evidently, the pediatric and young adult population would benefit most from such a tis‐
sue engineered aortic valve. The valve’s ability to grow as the recipient grows and matures,
eliminates the need for repetitive surgeries. [2-7].
Foundational principle of regenerative medicine is restoring the native tissue structure and
function by providing a microenvironment necessary to promote tissue regeneration. Tissue
engineering scaffolds are biomaterials designed to create this microenvironment and to pro‐
mote tissue regeneration [8]. The traditional tissue engineering paradigm for creating trileaflet
heart valves consists of harvesting autologous cells from the patient, expanding the cells in vi‐
tro, and subsequently seeding the cells into a biodegradable scaffold. The cell-scaffold con‐
structs are conditioned in a bioreactor to promote extracellular matrix formation (ECM), while
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the scaffold is degraded [9]. Although this approach leads to an autologous, living heart valve,
the in vitro process is a very costly and time consuming procedure. Therefore, a novel approach
emerged from this, in which the in vitro phase is completely omitted, the so-called in situ tissue
engineering, or ‘guided tissue regeneration’ (figure 1). This approach relies on the body’s nat‐
ural regenerative potential and uses the human body as a bioreactor [4]. Key to this process is
the use of a functional scaffold, capable of host cell repopulation and subsequent in situ tissue
remodeling. After implantation, cells will colonize the scaffold to form tissue, while the scaf‐
fold withstands physiological stresses and strains from its hemodynamic environment and
may gradually degrade [2,4]. Clearly, these characteristics put more stringent demands on the
biomaterial used, as it should provide both mechanical strength and the cellular niche, balanc‐
ing between material degradation and tissue formation. The scaffold can be biological or syn‐
thetic or a combination of both (a hybrid scaffold), loaded with bioactive components and/or
cells to provide stimuli for favorable host cell repopulation, differentiation and tissue forma‐
tion. The in situ approach allows for the minimization of risks and costs associated with cell
and tissue culture, while providing off-the-shelf availability.
Figure 1. (A) The in situ tissue engineering paradigm in which the scaffold is directly implanted, omitting lengthy in
vitro conditioning phases. (B) The scaffold consists of the bare biomaterial (i), which may harbor incorporated bioac‐
tive moieties (ii) and/or cells (e.g. bone marrow stromal cells) seeded directly prior to implantation (iii). (C) Hypothe‐
sized mechanism of in situ heart valve tissue engineering: after implantation, the scaffold will trigger the host immune
response, leading to recruitment of various immune cells and macrophage infiltration. The infiltrated cells secrete cy‐
tokines and growth factors to attract additional immune cells, as well as tissue cells, originating from surrounding tis‐
sue and/or circulating (progenitor) cells. Endothelial cells cover the blood-scaffold interface and activated
myofibroblasts migrate into the scaffold to produce extracellular matrix. Scaffold degradation correlates to a decrease
in pro-inflammatory stimuli, eventually leading to resolution of inflammation. Ideally, the valve remodels into the
physiological three-layered structure with endothelial cells covering the blood-contact area and quiescent myofibro‐
blasts as valve interstitial-like cells populating the spongiosa layer. Illustration by Anthal Smits.
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The in situ tissue engineering approach is heavily reliable on the wound healing response. Both
the injury incurred during the implantation process and the host inflammatory response to
the implanted biomaterial and its degradation products, influence the local microenvironment
created by the scaffold. The biomaterial intensifies the inflammatory response by inducing a
foreign body response (FBR), propagated by infiltrating immune cells [10,11]. This response
is characterized by the presence of macrophages and their fusion into multinucleated giant
cells associated with chronic inflammation arising from the persistent presence of a foreign
body. The FBR, especially inflammation, may drive valve calcification. However, inflamma‐
tion is not merely a detrimental response to biomaterial scaffolds. Rather, it can be considered
as a natural agent of tissue remodeling, orchestrated by various cell types and potent signaling
molecules. By unraveling the inflammatory response towards the foreign biomaterial and the
triggers for pathological outcome, targets may be identified to control the inflammatory
response through modifications of the biomaterial. The goal is to develop strategies that
harness the beneficial aspects of the inflammatory response, while limiting its potential
deleterious effects by modulating the inflammatory response towards regeneration.
This chapter deals with the use of biomaterials for in situ heart valve tissue engineering and
the immune response to the implanted biomaterial. The FBR to biomaterials is discussed,
leading to biomaterial design approaches directed to immunomodulation towards tissue
regeneration, identifying pitfalls as well as current research challenges for this innovative
technology.
2. Biomaterial scaffolds
Biomaterials are materials that interact with the body and its cells. As such, they are central to
many strategies for regenerative medicine. They are employed as vehicles for transplanting
(progenitor) cells, timed and localized delivery of bioactive moieties, and/or as 3D scaffolds
for tissue engineering. Scaffolds are biomaterials designed to create a microenvironment that
promotes regeneration. Besides creating and maintaining a defined space for tissue growth,
biomaterial scaffolds also provide mechanical stability, and support cell adhesion and
migration. Ideally, a scaffold for tissue engineering should be bioresorbable, biocompatible
and have a highly porous macrostructure necessary for cell growth, nutrient supply, and waste
removal [2,3,6,8,12]. By engineering the proper cellular niche, such scaffolds can provide an
environment suitable to modify host responses and direct cell survival, migration,
proliferation, differentiation, as well as matrix formation and remodeling. The premise is that
in order to unlock the full potential of the cells, at least some aspects of the native 3D tissue
environment associated with their renewal, differentiation and organization needs to be
mimicked in the applied scaffold materials [3].
2.1. Biomaterial scaffold use in in situ heart valve tissue engineering
Trileaflet heart valves are sophisticated tissues with an anisotropic three-layered structure,
optimized to withstand the repetitive hemodynamic loads it is subjected to. A human heart
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valve opens and closes approximately 100.000 times per day, resulting in cyclic changes in the
shape, dimensions, and stress of its leaflets and supporting structures. Furthermore, rather
than being a purely passive structure, heart valves consist of active components that allow
them to adapt to changes in the hemodynamic environment to a certain degree. This puts
stringent demands on biomaterial scaffolds used for heart valve tissue engineering, in
particular on the mechanical properties. The hemodynamic environment requires a strong
biomaterial bearing the repetitive and substantial mechanical stresses applied, especially in
the aortic position. This calls for excellent elastic and fatigue properties of the scaffold. A
successful tissue engineered heart valve must not only accommodate the resulting
deformations, but also have ongoing strength, flexibility, and durability, beginning at the
instant of implantation and continuing throughout the lifetime of the recipient [2]. For the in
situ tissue engineering approach, this means the scaffold has to maintain valve functionality
while ECM is formed and remodeled and the biomaterial is degraded in situ. In contrast, for
the traditional in vitro tissue engineering approach the load-bearing function of the biomaterial
is overtaken by ECM in vitro, prior to implantation. This balance between scaffold resorption
and synthesis of new matrix by the host’s cells is one of the main challenges in designing
scaffolds for in situ tissue engineering [4].
2.1.1. Biological scaffolds
The ECM is the natural scaffold for tissue and organ morphogenesis, maintenance, and
reconstruction following injury, and is associated with constructive tissue remodeling [12].
The ECM proteins are potent regulators of cell adhesion and activation, and provide a 3D
scaffold for cellular organization and migration. They provide mechanical support and store
and mobilize signaling molecules. The fibrous ECM structure is provided by collagen, elastin,
and fibrin, while non-fibrous proteins as fibronectin and laminin are domains for cell-matrix
interactions. This protein scaffold is embedded in a gelatinous matrix composed of
glycosaminoglycans (GAGs) and proteoglycans. It serves as a lubricant and as a reservoir for
signaling molecules, regulating their distribution and mode of action serving cell-matrix
interactions, and activation of enzymes and mediators [11]. Hence, ECM serves as a native
modulator of cell activity, also in immune responses and tissue repair. The 3D organization of
its components and the complexity of the composition distinguish the native ECM from
synthetic scaffolds [4,12,13]. Consequently, the use of a decellularized valve is currently the
predominant choice as scaffold material for application in in situ engineering of heart valves.
In contrast to cross-linked bioprostheses, decellularized xenografts or homografts allow for
infiltration of host cells and matrix remodeling, which may render an autologous, living
replacement valve in time. Upon decellularization, the xenograft or homograft is depleted of
cells and cellular components. The decellularized matrix possesses a native-like geometry and
structure with mechanical properties and physiological hemodynamics similar to its native
counterpart [3,4,14]. Signaling components present in the matrix provide natural cues to dictate
cell adhesion, proliferation, and growth. With respect to biocompatibility, it is crucial to
remove all cellular components, without harming or altering the matrix properties by the
decellularization treatment [15]. The method of decellularization strongly determines the
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degree of preservation of matrix integrity, as well as the efficiency of cell removal. Various
decellularization techniques are being studied in an effort to suppress the immunogenic
potential of such biological matrices while retaining matrix integrity [2,4,5,7,14]. Results from
studies on recellularization of decellularized homografts and xenografts in animal models are
controversial, as reviewed elsewhere [2-4,7,16]. In decellularized aortic valves, residual
devitalized cells and their epitopes are primary initiators of valve calcification leading to failure
of this bioprosthetic valve [7,17]. It is suggested that inflammation inhibitory factors, naturally
present in the ECM, are lost due to the decellularization treatment, accounting for the
activation of granulocytes and the initiation of the immune response [4]. Furthermore,
xenografts are associated with the risk of immunogenic reactions or disease transmission and
availability of homografts is limited. To overcome these issues, recent studies have suggested
the use of homologous decellularized tissue engineered heart valves. For this, heart valves
were engineered in vitro using adult saphenous vein cells seeded onto a synthetic polyglycolic
acid (PGA)/poly-4-hydroxybutyrate (P4HB) scaffold. After conditioning the cell-scaffold
construct in an in vitro bioreactor, the tissue engineered valve was decellularized and used as
a starter matrix for subsequent recellularization and remodeling in situ [18].
An alternative, natural resorbable scaffold material suitable for in situ tissue engineering and
studied extensively is small intestine submucosa (SIS) [2,3,13]. SIS consists almost entirely of
acellular collagen so there is no need for these substrates to undergo extensive decellularization
procedures, making it an attractive alternative to decellularized matrices [3]. The success of
SIS has been attributed to its intrinsic ECM proteins, cytokines, and growth factors, showing
rapid remodeling by the host tissue and exhibiting good vascularization and tissue growth
without excessive inflammation and FBR [2]. With respect to heart valve tissue engineering,
complete valvular replacements from SIS have been produced demonstrating remodeling
potential in vivo [19]. As for all animal derived materials, a disadvantage of using SIS is the
risk of transferring zoonoses and its availability may be a limiting factor when homograft
material is used [3,14]. Further studies should clarify the underlying mechanisms involved
before translating the use of decellularized matrices as heart valve scaffolds to human clinic.
2.1.2. Synthetic scaffolds
Synthetic scaffolds have the advantage that they can be tailored to demands, offering precise
control of various aspects, such as mechanical properties, chemical properties, degradation
rate, as well as the immunogenic potential [7,8]. However, this level of control comes at a price
in the sense that multi-disciplinary in-depth knowledge is required to engineer a scaffold
appropriate for in situ tissue engineering. Engineering of synthetic scaffolds is a discipline that
spans multiple length-scales. On the macroscale, a scaffold should exhibit mechanical
properties appropriate to fulfill its function. The 3D architecture affects the global mechanical
properties of the scaffold, but additionally, on the microscale, it influences cell infiltration and
organization (e.g. by contact guidance). Apart from the global mechanical properties of a
scaffold, the local mechanical properties, such as material surface stiffness, determine the
stimuli experienced by the cells. Surface chemistry (e.g. hydrophobicity/hydrophilicity) has a
major effect on cell- and protein-biomaterial interactions and with state-of-the art incorpora‐
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tion of bioactive or even bioresponsive molecules, scaffold engineering has advanced down
to the nanoscale [3]. This emphasizes that not only the choice of biomaterial but also the method
of processing is of key importance in scaffold development.
Synthetic biodegradable materials, such as PGA, P4HB, polylactic acid (PLA), polycaprolac‐
tone (PCL) and copolymers, are the main biocompatible materials of choice, varying in their
rates of degradation and manufacturing possibilities [2-4,6,7,14]. Their degradation rate can
be tailored by varying their copolymer ratio [3]. Fast-degrading scaffolds such as PGA/P4HB
have been used extensively as scaffolds for in vitro tissue engineering procedures of heart
valves [9,20,21]. Whereas the use of synthetic scaffolds in traditional in vitro tissue engineering
is abundant, experience with the use of synthetic scaffolds for in situ tissue engineering of heart
valves is rather limited. However, recent studies applying synthetic scaffolds for small-caliber
blood vessels demonstrate the ground-breaking potential of such scaffolds for endogenous
regeneration. Small-diameter nanofibrous PCL grafts showed fast endothelialization and ECM
formation in the systemic circulation of a rat model [22]. Vascular grafts composed of a
nonwoven PGA mesh with a PCL/Poly-L-lactic acid (PLLA) copolymer, seeded with bone
marrow stromal cells, demonstrated regeneration of mature blood vessels in situ via an
inflammation-mediated response in a mouse model [23], as well as in clinical trials [24]. To
improve mechanotransduction from the biomaterial to the cells, Wu et al. employed a fast
degrading elastomeric graft, consisting of poly(glycerol sebacate) (PGS), resulting in fast in
situ regeneration of neoarteries with mechanical properties and functionality similar to the
native vascular tissue [25]. Alternatively, Yokota et al. developed a hybrid scaffold consisting
of a collagen sponge with layered PGA and PLLA, resulting in regeneration of the canine
carotid artery [26]. Although these results demonstrate the great potential of synthetic or
hybrid scaffolds for in situ tissue engineering, translating these results to heart valves is not
trivial due to the complexity of mechanical loads and high-demanding function of the heart
valve. Furthermore, slow and/or incomplete polymer degradation may result in excessive
chronic inflammation, possibly leading to fibrosis and hampered valve function.
Despite these challenges to overcome, synthetic scaffolds have the potential to offer a strong
cost-effective off-the-shelf alternative for heart valve replacements, yielding them very
interesting for future clinical application.
2.2. Modulating the immune response
Independent of the biomaterial, the injury incurred during the implantation process will
trigger an immune response, due to the disruption of host tissue and induction of cell damage.
However, the extent of the inflammatory response evoked is dependent on location,
implantation procedure, and biocompatibility of the biomaterial [14,27]. The natural human
host response to the scaffold is an excellent target to modulate and control cell and tissue fate.
Valvular regeneration is hypothesized to start with a rapid infiltration of the scaffold by
monocytes. These monocytes differentiate into macrophages and attract progenitor cells that
differentiate into tissue-producing cells. In addition, the macrophages themselves may
differentiate into tissue-producing cells. Next, clearance of the macrophages occurs and
extracellular matrix is formed and remodeled toward the natural heart valve matrix
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architecture with quiescent cells. Detailed understanding of this response will provide
guidelines to achieve cell and tissue homeostasis, while preventing adverse tissue develop‐
ment (e.g. fibrosis) by mitigating early cellular responses. As the nature of the infiltrating cells
in the scaffold and their differentiation is believed to tune the balance of later stage tissue
formation towards regeneration or fibrosis, controlling the endogenous production or
presentation to the cells of key regulating cytokines in these early processes is essential. Thus,
insights in the sequential cell influx and cytokine production and their role in cell differentia‐
tion/polarization and tissue formation, will allow the development of optimized scaffolds for
in situ heart valve tissue engineering applications.
3. The immune response to biomaterials
The defensive response of the human body to invasion by disease-causing entities is referred
to as the immune response. In general, its main function is to resolve the infection, restore the
tissue damage and reestablish a state of homeostasis. The ideal response is rapid and
destructive when necessary, yet specific and self limiting [28]. The immune response consists
of two stages: the innate response and the adaptive response (figure 2). The innate immune
response refers to the antigen-nonspecific defense mechanism that a host uses immediately or
within several hours after exposure to a pathogen or other foreign entity, e.g. a biomaterial.
The response is aimed at the recognition and removal of the entity, inhibiting infection and
inducing a state of inflammation. When the innate immune response is outrun by a continuing
infection and antigen is drained to regional lymph nodes, the adaptive immune response is
triggered. Adaptive immunity is antigen-specific, generating responses that are tailored to
maximally eliminate pathogens and cells displaying non-self antigens. A key feature of
adaptive immunity is the development of immunological memory, in which specific
antibodies are generated [29,30]. Synthetic biomaterials are thought not to initiate an adaptive
response because they are typically not immunogenic. However, cells and mechanisms
involved in the initiation of an adaptive immune response have been found at sites of synthetic
implants, suggesting the involvement of an adaptive response in the immune response to
biomaterials [11]. In in situ tissue engineering, an immune response is inevitable and its
beneficial aspects, i.e. dead cell removal and initiation of wound healing, must be harnessed
while the potential deleterious effects, i.e. excessive inflammation and fibrosis, must be limited.
3.1. The acute and chronic inflammatory response
The classification ‘acute’ or ‘chronic’ is primarily defined by the duration of the inflammatory
response and the type of cells infiltrating in response to pro-inflammatory signals [27]. As part
of the innate immune response, the acute inflammatory response occurs in the first days after
implantation and is characterized by the presence of blood-derived polymorphonuclear
leukocytes (PMNs, or granulocytes), predominantly neutrophils. The infiltrating cells cause a
state of inflammation to develop within the tissue, generally described by the local
accumulation of fluid accompanied by warming (calor), pain (dolor), reddening (rubor),
swelling (tumor), and functional changes (functio laesa). These cells secrete reactive oxygen
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intermediates (ROIs) and inflammatory cytokines, including interleukin-1β (IL-1β), tumor
necrosis factor-α (TNF-α), and interferon-γ (IFN-γ), which orchestrate the character and
degree of the subsequent immune response [31]. Their actions can, besides eliminating the
pathogen or other foreign entity, also cause secondary damage to the surrounding tissue.
Controlling the numbers and types of immune cells at the implant site has the potential to
reduce secondary tissue damage and promote regeneration [8].
The inflammatory response prolonging within subsequent weeks, months or even years after
implantation is referred to as the chronic inflammatory response. Ideally, the chronic phase of
the inflammatory response is avoided through adequate and quick elimination of the disease-
causing entity during the acute phase. Chronic inflammation develops as inflammatory stimuli
persist at the implant site, with macrophages representing the driving force in continuing the
inflammatory response, mediating prolonged expression of cytokines, i.e. IL-1β and TNF-α
[11]. Implantation of a biomaterial can intensify the inflammatory response by inducing a FBR,
propagated by the infiltrating macrophages, which influences subsequent wound healing.
Figure 2. Overview of the immune response to a biomaterial; pathogen-associated molecular patterns (PAMPs), dam‐
age-associated molecular patterns (DAMPs), polymorphonuclear leukocytes (PMNs), dendritic cells (DCs), reactive oxy‐
gen intermediates (ROIs), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), monocyte
chemotactic protein-1 (MCP-1], foreign body response (FBR), endothelial cells (ECs), foreign body giant cells (FBGCs),
transforming growth factor-β (TGF-β), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF),
vascular endothelial growth factor (VEGF).
3.2. Mediators of the immune response
The complete process from innate immune response to wound healing is tuned by a broad
spectrum of cytokines and growth factors. Cytokines are a large family of proteins, peptides
and glycoproteins, recognized as intercellular signaling immunomodulators [27]. Cytokines
are produced by cells and affect the behavior of other cells by binding to specific receptors on
their target cells. The term chemokine refers to a specific class of cytokines that is involved in
guiding leukocytes to sites where their functions are needed, and as such, have a central role
in inflammatory processes. This migration of cells to the site of interest via unidirectional
movement towards an increasing gradient of a chemical signal is called chemotaxis [27,30].
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Chemokines are not only involved in orchestrating cellular migration in inflammation and
wound healing, but also play roles in hematopoiesis, angiogenesis, and tumor metastasis [10].
The secreted chemical mediators usually have a very short half-life due to their high
susceptibility to proteolytic degradation. Local linkage to the ECM protects them from
enzymatic cleavage, while others may become inactive when bound and can only act when
released by matrix proteolysis [11]. Hereby, chemical mediators and ECM proteins collaborate
in creating a distinct cellular niche that regulates tissue regeneration.
3.3. Initiation of the innate immune response
Implantation of a biomaterial scaffold typically leads to thrombus formation and initiation of
an acute immune response by activation of the coagulation system, complement system,
fibrinolytic system, and platelets. Interaction of the biomaterial with blood leads to protein
deposition on the biomaterial surface forming a provisional matrix, which affects subsequent
leukocyte adhesion interactions [8]. Synthetic polymers, their degradation products and/or the
associated provisional matrix activate the complement cascade, marking the biomaterial as
being foreign. Phagocytic cells are recruited to the implant by the chemokines released from
the provisional matrix and surrounding cells. These phagocytic cells adhere to the matrix
surface and further enhance secretion of inflammatory products.
3.3.1. Blood protein precipitation
Upon contact with blood, the blood-biomaterial interaction leads to adsorption of blood
proteins, dependent on the biomaterial surface properties [10,11,29,31,32]. The adsorption of
endogenous proteins from blood or interstitial fluid onto the surface of the biomaterial, rather
than the biomaterial itself, dictates the immune cell response to implanted biomaterials [27].
All other host components, including leukocytes, encounter and/or interact with this surface
as an adhesion substrate. It serves as a provisional matrix, which may also contain a milieu of
cytokines, chemokines, or other bioactive agents. This provisional matrix furnishes structural,
biochemical, and cellular components to the processes of wound healing and FBR. It can be
seen as a naturally derived, biodegradable sustained release system in which bioactive
moieties are released to control subsequent phases of wound healing [10].
The precipitation of proteins from blood and tissue occurring immediately after implantation
determines the activation of the coagulation cascade, the complement system, platelets and
immune cells. The proteins guide their interplay, leading to the formation of the provisional
matrix and to the onset of the immune response [11,29]. The adsorbed protein layer includes
complement activation fragments, immunoglobulin G (IgG), fibrinogen, fibronectin, and
vitronectin. Fibrinogen and fibronectin bind a large number of extracellular macromolecules
as well as cell surface proteins, providing a matrix for cell proliferation and organization [33].
Whereas complement and fibrinogen mainly contribute to the activation of inflammatory cells,
fibronectin and vitronectin are critical in regulating the inflammatory response to biomaterials
[11]. The composition of the protein layer changes over time, described as the Vroman effect
[10,29]. Adsorbed proteins may desorb rapidly and, therefore, present time-dependent
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variations in the type and level of proteins which cells encounter. The highest mobility proteins
of the blood serum generally arrive first, e.g. albumin and globulin, and are later replaced by
less motile proteins that have a higher affinity for the biomaterial surface, e.g. fibronectin and
factor XII.
Complement receptors function as a non-specific aid in detection and removal of foreign
materials. Activation of the complement system leads to subsequent reactions in host defense
and functions as one of the players in the tight cross-talk between the different cascade systems,
platelets, and leukocytes, inducing clotting and inflammation. The complement system is
activated by the coating of the implant with complement activation fragments within the
provisional matrix, and through release of anaphylatoxins, i.e. C3a and C5a, which are chemo-
attractants for leukocyte infiltration and cause leukocyte activation [32,34]. Upon complement
activation, proteases in the system cleave specific proteins to release cytokines, e.g. TNF-α,
IL-1β, IL-6, and IL-8, and initiate an amplifying cascade of further cleavages. Furthermore, it
contributes to the onset of the inflammatory response by triggering degranulation of mast cells,
attraction and activation of PMNs and monocytes, induction of ROI-release by PMNs,
supporting platelet adhesion and activation, and promotion of tissue factor expression by
monocytes and PMNs on biomaterial surfaces [11]. Destruction of host cells is prevented by
the presence of membrane-bound complement regulatory proteins, e.g. CD46, CD55, and
CD59 [29].
Blood coagulation on biomaterials requires the combination of contact activation by factor XII,
platelet adhesion and their activation by thrombin. This leads to the cleavage of fibrinogen to
fibrin and subsequent clot formation. Platelet adhesion and activation, through adsorbed IgG
and fibrinogen, mediates neutrophil reactive oxygen generation and monocyte tissue factor
expression, leading to neutrophil and monocyte adhesion [29]. Platelets trapped in the fibrin
clot, as well as fibroblasts and leukocytes themselves are major resources of chemo-attractants
at the site of implantation, initiating and modulating inflammatory reactions and immune
responses [35,36].
Cell adhesion and activation on biomaterials primarily occurs through interaction of adhesion
receptors with the adsorbed proteins. The major adhesion receptors of leukocytes are
represented by integrins, which regulate aggregation, immune functions, cell migration,
matrix deposition, and wound contraction [33]. Surface integrin molecules allow cells to
migrate through the ECM and mediate signal transduction between the cell and its
environment, enabling the cell to respond to its environment. Integrin molecule engagement
on leukocytes promotes leukocyte survival, activation, and differentiation [29]. Ligands for
integrin receptor binding and cellular adhesion are provided by the adsorbed proteins,
including fibrinogen, IgG, iC3b, fibronectin, and vitronectin [10].
3.3.2. Pattern recognition
Besides recognition of biomaterials through adhesion receptors, i.e. integrins, immune cells
are activated by another type of receptor-ligand interaction that is based on pattern
recognition. A class of molecules classically defined as pathogen-associated molecular pattern
(PAMP) molecules, alerts the innate immune system and triggers defensive immune
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responses. PAMPs include lipopolysaccharide (LPS), viral RNA and bacterial peptidoglycans,
which interact with dedicated receptors on immune cells, the pattern recognition receptors
(PRRs) [8,11,28,29,35,37,38]. These receptors are specialized in the recognition of microbial
components that are chemically distinct from the host’s endogenous molecules [39]. PRRs
include transmembrane Toll-like receptors (TLRs), cytoplasmic NOD-like receptors (NLRs),
and cytoplasmic C-type lectin receptors (CLRs) [28,37]. The TLR family is a well-known family
of PRRs, in which each member recognizes a specific set of molecular patterns. For example,
TLR2 and TLR4 recognize damaged ECM by binding breakdown products of hyaluronan
cleaved in tissue damage, while TLR7, TLR8, and TLR9 recognize host RNA and DNA [28].
TLRs are expressed on e.g. platelets, macrophages, dendritic cells (DCs), neutrophils, and
endothelial cells [36,37]. Tissue-resident macrophages and DCs, both functioning as antigen-
presenting cells (APCs), are most influential in early PRR-signaling and are the primary
inducers of an inflammatory reaction [28,39].
An inflammatory response can, besides initiation by PAMPs, also be initiated by several
endogenous molecules interacting with signaling receptors. These innate danger signals are
described as endokines or alarmins, but are also known as damage-associated molecular
patterns (DAMPs) [11,35,38,40]. These signals have immunostimulatory effects and include an
array of structurally diverse, multifunctional host proteins that are rapidly released during
infection or tissue damage, e.g. after biomaterial implantation. The resulting necrotic cell death
leads to the release of cytoplasmic and nuclear components that contain DAMPs, recognized
by PRRs expressed by leukocytes. In addition, proteases and hydrolases released from dead
cells modify extracellular components to generate mediators (e.g. complement fragments) or
other DAMPs (e.g. ECM fragments), which can activate leukocytes [39]. DAMPs have
intranuclear, intracellular and/or extracellular functions in mobilizing and activating receptor-
expressing cells engaged in host defense and tissue repair, e.g. macrophages and DCs. One of
the members of the DAMP family is the group of high-mobility-group box (HMGB) proteins,
which are chromosomal proteins helping in transcription, replication, recombination, and
DNA repair. HMGB-1 is one of the best known proteins within this family and is released by
necrotic cells, cytolytic cells, and cells stimulated by pro-inflammatory stimuli. It was shown
to have extracellular activity as a chemokine, attracting neutrophils and mononuclear
inflammatory cells [28,39,40]. Other members of the DAMP family include interleukins, heat-
shock proteins, defensins, eosinophil-derived neurotoxin, macrophage-/PMN-derived
cathelicidins, and nucleosomes. Injury-related TLR-ligands are small hyaluronan fragments,
fibrinogen, and fibronectin, of which the latter two are present in the adsorbed protein layer
on a biomaterial surface [28].
Induction of inflammation through pattern recognition leads to activation of the receptor
expressing cell. When a ligand has bound to a PRR, activation signals are sent out, which
initiate signaling pathways leading to the activation of transcription factors, notably nuclear
factor κB (NF-κB). This factor migrates into the nucleus and mediates gene transcription and
production of inflammatory mediators, such as chemokines, adhesion molecules, growth
factors, and pro-inflammatory cytokines, especially TNF-α, and IL-1, which themselves also
mediate activation of NF-κB [37]. Many molecules with important functions in immunity and
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repair mediate their effects through activation of the NF-κB pathway. Transcriptional control
of inflammation by NF-κB during the immune response has emerged as one of the most
important signaling cascades in the regulation of the inflammatory response [35].
3.4. Cell recruitment in the acute inflammatory response
The acute inflammatory response is driven by fast acting leukocytes, mostly neutrophils and
macrophages, as the primary defense against nonspecific infecting entities [11,27]. After
implantation of a biomaterial, inherently causing cell damage, these immune cells are activated
through the engagement of their integrins and PRRs with the protein-coated biomaterial
surface. The activation of immune cells leads to the initiation of inflammatory cytokine
production and subsequent chemokine recruitment of more immune cells, i.e. PMNs,
monocytes, and macrophages, but also endothelial cells and fibroblasts to the site of
implantation [28,35]. Activation of PMNs includes a phagocytic response and degranulation,
which subsequently leads to biomaterial degradation and potential damaging of the
surrounding tissue, prolonging the inflammatory response [11].
During the inflammatory response, macrophages and lymphocytes predominantly synthesize
and release immunoregulatory cytokines, e.g. IL-1β, IL-6, and TNF-α, and chemokines, e.g.
IL-8, monocyte chemotactic protein-1 (MCP-1), and macrophage inflammatory protein-1β
(MIP-1β). These are potent chemo-attractants and activation factors for inflammatory effector
cells such as PMNs, monocytes, macrophages, immature DCs, natural killer (NK) cells, and
lymphocytes. Changes in cellularly released chemical factors mediate additional cell
recruitment and activity [27]. The increasing influx of mononuclear cells over time is balanced
by a decreased infiltration of PMNs, leading to a decrease in PMN activation signals followed
by their apoptosis and engulfment by macrophages. Within two days after implantation PMNs
typically disappear from the site [11].
3.4.1. Neutrophils
Neutrophils are the most dominant cell type among the PMNs present in the acute
inflammatory response. They are phagocytic leukocytes containing granules and are activated
by pro-inflammatory cytokines, such as IL-1β, TNF-α, and IFN-γ [35]. The life span of a
neutrophil inside the blood stream is 12 hours, but increases to 24-48 hours upon activation
outside the vasculature [27,39]. Crucial mediators for neutrophil recruitment in acute
inflammation are chemokines and their receptors, e.g. IL-8 [35]. The primary function of IL-8
is induction of the chemotaxis of neutrophils, with their arrival at the site within hours after
injury, followed by a later influx of monocytes [38].
Neutrophils eradicate foreign entities by immediate phagocytosis, a process by which solid
particles are uptaken by the cell. After phagocytosis of the biomaterial, neutrophils die, and
are, together with other material debris, cleared by resident macrophages [27]. This uptake
promotes anti-inflammatory lipoxin production by the macrophage, which down-regulates
further neutrophil recruitment and activity, while promoting monocyte migration [39]. When
neutrophils detect TNF-α, but do not directly encounter any exogeneous particles, they
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mobilize and release their granules into the extracellular space, a process called degranulation,
to create an inhospitable environment for nearby foreign entities [28]. The granules of
neutrophils are loaded with proteases, which, together with the production of ROIs and
reactive nitrogen intermediates (RNIs), leads to the denaturation of proteins, disruption of
lipids, and damaging of DNA [28,39]. Upon degranulation, the neutrophil reorganizes its
surrounding microenvironment and promotes the recruitment of additional immune
responsive cells, mainly monocytes, but also generates secondary damage to the host tissue
and cells [8,28]. Therefore, neutrophil activation has to be tightly controlled to avoid excessive
tissue damage while enabling the rapid recruitment of monocytes [39].
3.4.2. Monocytes
After neutrophils, monocytes enter the site of implantation and subsequently mature into
tissue macrophages or DCs. Bone marrow precursors give rise to the monocytes in the blood,
which circulate for a few days before they migrate into the tissue and mature [41]. Monocytes
are recruited by cytokines and chemotactic factors, released by resident macrophages and
neutrophils [27]. In general, monocytes reach maximum numbers 24-36 hours after injury [37].
There is a guided movement of monocytes in response to chemokines and other chemo-
attractants [10]. MCP-1, also known as C-C chemokine ligand 2 (CCL2), binds to C-C
chemokine receptor 2 (CCR2) and mediates monocyte recruitment [42]. Although expression
of CCR2 is restricted to only a few cell types including monocytes, most (if not all) nucleated
cells express MCP-1 in response to activation by pro-inflammatory cytokines or stimulation
of innate immune receptors. A hypothesis on the mechanism of action of MCP-1 in monocyte
recruitment from the bone marrow is that MCP-1 dimerizes and associates with tissue GAGs,
creating a gradient which guides monocytes toward the site of infection or inflammation [42].
In the blood, monocytes are not a homogeneous population of cells. Human monocytes are
divided into subsets according to their surface expression of CD14 and CD16 [39,42]. CD14 is
a PRR that can recognize and bind various structures from invading microbes (e.g. LPS), while
CD16 is a receptor binding IgG antibodies [41]. CD14++CD16- monocytes are the most preva‐
lent monocyte subset present in the blood (~85% of total monocytes) and express CCR2 [43].
The CD16+  monocyte population comprises  two subsets,  CD14++CD16+  and CD14+CD16++
monocytes [41,42]. There appears to be a developmental relationship between these differ‐
ent subtypes in that, during the course of an inflammatory reaction, the CD14++CD16- mono‐
cytes first develop into CD14++CD16+ monocytes to then become CD14+CD16++ monocytes.
Hence, CD14+CD16++ monocytes may represent a more mature subset [41]. The precise role of
the different monocyte subsets in initiating immune responses remains unclear, although
CD14++CD16- monocytes are believed to contribute more effectively to pathogen clearance
while CD14+CD16++ monocytes show a patrolling role and account for more vigorous produc‐
tion of pro-inflammatory cytokines [39,42].
At the site of implantation, monocytes become activated and develop into DCs or mature tissue
macrophages, undergoing a phenotypic change. This process is directed by mediators present
in the microenvironment, such as cytokine receptors, TLRs, and complement receptors, which
are crucial for the proper adaptation of cell function to the specific requirements at the site.
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[11,35]. For example, TLR-activated monocytes produce IL-10, which has a central role in
preventing excessive inflammation [38]. Additionally, there is substantial debate about
whether specific monocyte populations give rise to specific tissue macrophages [39,44]. It has
been suggested that monocytes continue maturing in the blood and can be recruited to the
tissue at various points during this maturation continuum. The point at which they leave the
blood may define their function [42].
3.4.3. Dendritic cells
Dendritic cells (DCs), monocytes, and macrophages are closely related, as blood monocytes
can differentiate into macrophages and DCs and, in their turn, DCs can differentiate into
macrophages [41]. The main function of DCs is to function as APCs, processing foreign material
and presenting it on its surface to other immune cells, e.g. T-lymphocytes (T cells) [45]. They
act as messengers between the innate and adaptive immune response, initiating the T-cell
response [29]. Besides their presence as resident cells in tissues, they are also found in the blood,
circulating in an immature state. Upon activation, DCs migrate to the lymph nodes and interact
with lymphocytes to initiate and modulate the adaptive immune response [30].
By triggering receptors and signaling cascades of the pathogen recognition system,
biomaterials activate DCs through the adherent protein layer [11,29]. DC maturation is
promoted or inhibited depending on which PRR is engaged, leading to immunity or tolerance,
respectively. Immunogenic DCs may prolong the immune response to biomaterials and delay
wound healing, while tolerogenic DCs are capable of down-regulating the immune cells and
resolve inflammation [11]. Activated immunogenic DCs promote T-cell proliferation and
secrete pro-inflammatory cytokines, e.g. IL-1β, IL-6, IL-12, and TNF-α, which further amplify
DC maturation by autocrine stimulation. The immature and semi-mature tolerogenic DCs are
promoters of tolerance and secrete e.g. IL-10 and TGF-β [45]. Besides PRR engagement, integrin
signaling due to binding of DCs to ECM proteins on the biomaterial, may act as an alternative
mechanism of DC maturation and activation and should be taken into account in the strategy
of modulating immune responses to biomaterials.
3.4.4. Mast cells
Mast cells are a leukocyte subset represented in most tissues and are best known for their role
in allergy. However, they play an important protective role as well, being intimately involved
in host defense and wound healing. In the innate immune response, they are an important
source of pro-inflammatory mediators and cytokines, containing many granules that are rich
in histamine, and producing prostaglandins and cytokines that promote inflammation [35].
Together with tissue-resident macrophages and DCs, mast cells are responsible for the
recruitment of inflammatory cells in the innate immune response, i.e. chemotaxis of PMNs and
monocytes through secretion of e.g. IL-1β, TNF-α, and MCP-1 [11,28,29]. Besides functioning
in host defense mechanisms, mast cells participate more generally in the orchestration of
inflammatory responses, e.g. through IL-10 secretion, and tissue remodeling, through
secretion of proteases and anti-inflammatory cytokines, such as IL-4 [46]. They express a large
set of receptors allowing them to respond to a large variety of stimuli, with activation of specific
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receptors leading to specific actions. Therefore, mast cell functions are highly dependent on
the physiological context, as small differences in the mast cell environment may yield variant
or even opposite actions [46].
3.5. The chronic inflammatory response
Once neutrophils, monocytes and macrophages have entered the site of injury or infection in
the acute phase of the response, they collaborate to remove the foreign entity [39]. The
transition of the acute inflammatory response to the chronic inflammatory response is signified
by the departure of the PMNs and infiltration of more macrophages and lymphocytes, which
give rise to new tissue formation [8,10,31].
3.5.1. Macrophages
Generally, when the acute phase of inflammation has not sufficed to clear the source of
infection within the first 2 days after implantation, macrophages become the dominating force
in the persisting inflammatory response. Macrophages are recruited by many of the same
signals as neutrophils but have a longer life span. Tissue-resident macrophages have a life span
up to months [27,28]. The primary role of macrophages is to function as a common guardian
cell of which the main function in homeostasis is to clear the interstitial environment of
extraneous cellular material through phagocytosis [44]. Macrophages are professional
phagocytes with extraordinary synthetic and secretory capacities and exert key controlling
influences on wound healing and fibrosis responses [31].
A resting macrophage is activated by microbial products, immune complexes, chemical
mediators, certain ECM proteins, and T-cell-derived cytokines. An adherent macrophage on
a biomaterial is activated to initiate phagocytosis and cytokine secretion, hereby directing the
inflammatory and wound healing response to the biomaterial [10]. Several of the key
biomaterial-dependent chemokines and cytokines (e.g. IL-1β, IL-6, IL-8, and TNF-α) have the
potential to induce multiple autocrine and paracrine effects in the chronic inflammatory and
wound healing phases, as well as a time-dependent switch in cytokine secretion from acute to
chronic phase phenotype [31]. Uptake of apoptotic neutrophils can stimulate macrophages to
release mediators that suppress the inflammatory response, e.g. TGF-β, IL-10 and prostaglan‐
din E2 (PGE2) [39]. In bridging the innate and adaptive immune response, macrophages can
fuse to become multinucleated giant cells and act as APCs to activate leukocytes which are
responsible for the adaptive immune response, e.g. through expression of co-stimulatory
molecules that are essential for T-cell activation [27,37].
Beside their function as phagocytes and APCs, it is assumed that macrophages play a
prominent role in a successful wound healing response through the synthesis of growth factors
such as TGF-β, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF),
and vascular endothelial growth factor (VEGF), which promote cell proliferation and synthesis
of ECM molecules by resident cells [10,35]. TGF-β is a potential stimulator of ECM production,
promoting both fibronectin and collagen synthesis in fibroblasts, and decreasing collagen
breakdown. With respect to angiogenesis, bFGF is probably one of the major growth factor
The Immune Response in In Situ Tissue Engineering of Aortic Heart Valves
http://dx.doi.org/10.5772/54354
221
families involved, being strongly mitogenic for endothelial cells, directing their migration and
proliferation. PDGF recruits neutrophils and monocytes, stimulates the activation of
macrophages, and induces expression of TGF-β [33]. Production of VEGF by cells present in
the damaged microenvironment is induced by both IL-1β and IL-10, stimulating vasculogen‐
esis and angiogenesis [38].
3.5.2. Macrophage phenotypes
Macrophages show remarkable plasticity, which allows them to efficiently respond to
environmental signals and change their phenotype concordantly. The different macrophage
phenotypes are identified and distinguished according to markers present at the cell surface
and profiles of cytokine and gene expression. Both the acute and the chronic inflammatory
response can markedly alter the physiology of macrophages [44]. Furthermore, surface
topology and molecular organization of biomaterials affects macrophages, and the cell-surface
interaction can change quantity and identity of secreted pro-inflammatory cytokines and
chemokines, gene expression patterns, and downstream remodeling events [47].
Figure 3. Schematic representation of macrophage plasticity. Macrophages can adapt their phenotype in response to
environmental cues provided via paracrine or autocrine signaling. Illustrated are extremities within the continuous
spectrum of macrophage polarization states (‘M1’, ‘M2a’, ‘M2b’) (adapted from [11,44]). Illustration by Anthal Smits.
Two main macrophage phenotypes have been suggested, classified as “M1” and “M2”,
mirroring the T helper 1 (TH1) and T helper 2 (TH2) cell polarization [48,49] (figure 3). The pro-
inflammatory, cytotoxic macrophage phenotype, signified as M1, is characterized by the
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promotion of pathogen killing and is associated with classic signs of inflammation. These
classically activated macrophages are involved in killing intracellular pathogens, up-
regulation of pro-inflammatory cytokines, inhibition of anti-inflammatory cytokines, and
synthesis of oxygen and nitrogen radicals, making them a crucial part of host defense
[10,11,44,45,47]. Their activation is stimulated by pro-inflammatory cytokines, e.g. IFN-γ
(released by TH1 cells or NK cells), TNF-α (released by APCs), IL-1β, IL-6, and IL-12, but also
by PAMPs, DAMPs, hypoxia, and abnormal matrix, such as pathological collagen deposition
[11,29]. Activated M1 macrophages also secrete pro-inflammatory cytokines themselves, i.e.
TNF-α, IL-1, IL-6, IL-12, and IL-23, inducing TH1 cell responses [45]. Furthermore, they produce
low levels of anti-inflammatory IL-10 [29,48]. Macrophages activated by a biomaterial are
typically of the M1 phenotype and can promote the invasion of additional inflammatory cells
by secreting chemokines such as IL-8, MCP-1, and MIP-1β. They also secrete degradative
enzymes and display high phagocytic activity [11]. Via the production of a variety of enzymes
that degrade ECM components, such as matrix metalloproteinases (MMPs), collagenase, and
elastase, M1 macrophages are crucial in matrix destruction and tissue reorganization, allowing
them to quickly migrate through injured tissues [45]. However, prolonged activation of M1
macrophages can lead to tissue damage.
Immuno-regulation, tissue repair, and constructive tissue regeneration are promoted by the
anti-inflammatory macrophage phenotype, signified as M2. These macrophages inhibit pro-
inflammatory cytokine secretion, promote anti-inflammatory cytokine secretion, and up-
regulate mannose receptors which are necessary for FBGC-formation and play a role in matrix
remodeling [10,47]. This alternative macrophage activation is stimulated by the release of IL-4
and IL-13 by TH2 cells, cytokines (e.g. IL-10, TGF-β), glucocorticoids, and apoptotic cells
[29,35,50]. In contrast to M1 macrophages, M2 macrophages typically produce high levels of
IL-10 and low levels of IL-12, leading to TH2 cell responses [45,48]. These macrophages show
reparative actions by promoting angiogenesis, production of pro-fibrogenic factors resulting
in enhanced fibrinogenic activity of fibroblasts, over-expression of certain ECM proteins, and
differential secretion of MMPs and tissue inhibitors of metalloproteinases (TIMPs) [10,49].
The M2 phenotype can be divided into two subsets, i.e. wound healing (M2a) and regulatory
(M2b) macrophages (figure 3) [11,44]. Wound healing macrophages are mainly triggered by
IL-4, released by mast cells, granulocytes, or TH2 cells, which down-regulates pro-inflamma‐
tory cytokine secretion by the macrophage. These macrophages promote wound healing
processes by contributing to the production of ECM proteins, such as fibronectin, and by the
activation of fibroblasts [11]. Although M2a macrophages exert anti-inflammatory activities,
they are not capable of down-regulating immune responses. Regulatory macrophages are
triggered by a variety of signals, e.g. IL-10, apoptotic cells, immune complexes, and
glucocorticoids. Their main task is to limit inflammation and to dampen the immune response,
restoring homeostasis while limiting the development of fibrosis [11,49]. They achieve this by
releasing high levels of IL-10, which is a very potent immune-suppressive cytokine acting
through inhibition of IL-6 signaling and NF-κB activation [38].
Macrophages seem to retain their plasticity and respond to environmental signals. The
activation of stimulus-specific transcription factors is likely to dictate the functionalized
The Immune Response in In Situ Tissue Engineering of Aortic Heart Valves
http://dx.doi.org/10.5772/54354
223
polarization of macrophages through effects on inducible gene promoters with specific
features, translating signals in the microenvironment of the macrophage into a polarized
phenotype [51]. The progression from an inflammatory macrophage phenotype (M1) toward
a more regenerative/anti-inflammatory macrophage phenotype (M2a/b) correlates with a
change in cytokine secretion profile by T helper cells changing from type 1 (TH1) to type 2 (TH2),
promoting resolution of the inflammation [8]. The phenotype of a macrophage population can
change over time but a single biochemical marker to distinguish between populations has not
been identified [44]. It is suggested that macrophages possess a continuum of phenotypes for
distinct biological functions, showing overlap of biomarkers and functions for M1 and M2
macrophages [45]. The primary three macrophage phenotypes suggested here, i.e. pro-
inflammatory, wound healing, and regulatory, can blend into a continuum of secondary
phenotypes that serve a wide variety of functions [44]. It is also unknown whether
uncommitted macrophages are recruited to the site of scaffold remodeling and subsequently
stimulated to differentiate locally or whether phenotype-committed macrophages are
selectively recruited to sites of remodeling, depending on the antigens or substrates that are
present [47]. The molecular determinants that precisely control macrophage plasticity, e.g.
switching between polarization states, are to a large extend unknown, which makes targeting
transcription factors for modulatory aims a challenge [51].
3.5.3. Lymphocytes
In the chronic phase of the inflammatory response, lymphocytes appear at the site of
inflammation together with macrophages [31]. Lymphocytes play a role in the adaptive
immune response, involving major histocompatibility complex (MHC) class I and class II
molecules, expressed on the surface of APCs, and recognized by receptors and co-receptors
on T cells. In general, MHC class I molecules present peptide antigens derived from pathogens
that replicate intracellularly and whose proteins are present in the cytosol of the cell, to
cytotoxic CD8+ T cells. MHC class II molecules present peptides obtained from pathogens and
their products that are present in the extracellular milieu and have been taken up into the
endocytic vesicles of phagocytic cells, to helper CD4+ T cells. The CD4+ TH1 cells and cytolytic
CD8+ T cells migrate to the infected tissue, where they activate macrophages to kill antigen-
bearing pathogens. This response is referred to as the cell-mediated immune response. On the
other hand, CD4+ TH2 cells and B-lymphocytes (B cells) perform their functions in the lymphoid
tissues, where TH2 cells activate B cells to produce antibodies against target antigens, called
the humoral immune response [29,30].
Accumulation of T cells is associated with the expression of MCP-1 few days after injury, with
production of the chemokines interferon-γ-inducible protein-10 (IP-10), and monokine
induced by interferon-γ (MIG), of which macrophages appear to be a major source [35]. T cells
become activated via interactions with APCs, i.e. macrophages, DCs, and B cells, which present
processed antigens bound to MHC molecules on their cell surfaces. Additional co-stimulatory
interactions with specific molecules on APCs are required upon lymphocyte activation, i.e.
interaction between CD80 or CD86 on the APC and CD28 on the T-cell surface [30].
Characteristics of activation include expression of specific cell surface markers and production
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of the classic activation cytokines IL-2 and IFN-γ [31]. T cells will undergo clonal expansion
by proliferation and up- or down-regulation of their effector function. When T cells are
activated but not co-stimulated, they become anergic, a mechanism for suppression of
inappropriate immune reactivity. Via this mechanism, cells that may have been inappropri‐
ately activated, undergo apoptosis, and are removed by macrophages. For example, anti-
inflammatory IL-10 induces antigen specific anergy of T helper cells, helping in the prevention
of excessive inflammation [31].
Macrophages and lymphocytes are capable of activating each other through direct and indirect
mechanisms [31]. Activated T cells induce production of pro-inflammatory cytokines IL-1β,
TNF-α, and IL-6, and chemokines IL-8, MCP-1, and MIP-1β by macrophages in a contact-
dependent manner. T cells promote the adhesion of macrophages to biomaterials and their
subsequent fusion, as well as biomaterial-dependent cytokine production, having consequen‐
ces for the biocompatibility of the biomaterial [31]. NK cells, a lymphocyte subset next to T
and B cells, are potential sources of IL-4 and IL-13 and may promote the FBR by inducing
macrophage fusion into FBGCs [31].
3.6. Inflammatory resolution and wound healing
After the inflammatory stimulus has been eliminated, the ongoing inflammatory response
must be resolved to avoid excessive tissue damage and to initiate the healing process. During
the resolution of inflammation, further infiltration of leukocytes is prevented and removal of
debris from the inflamed site is promoted, thereby restoring tissue homeostasis [39]. The
process of resolution is an active process requiring signals that turn off neutrophil infiltration
and, at the same time, promote the uptake and clearance of apoptotic cells and debris. Lipid
mediators, e.g. lipoxins and resolvins, seem to have a key role in this process, and the resolution
of inflammation is accompanied by an active switch in the types of lipid mediator found at the
inflamed site [28,39]. During the inflammatory response, prostaglandins and cytokines that
amplify inflammation are generated by various cell types, including neutrophils, monocytes,
and macrophages. Following this, PGE2 and prostaglandin D2 (PGD2) gradually promote the
synthesis of anti-inflammatory and pro-resolving mediators, such as lipoxins. Another
mechanism of inflammatory resolution is inactivation of chemokines through cleavage by
MMPs, terminating inflammatory cell influx [39].
The initiation of wound healing is generally marked by the arrival of fibroblasts for the
production of ECM proteins, and of endothelial cells for angiogenesis. They occur within the
3 to 5 days of monocyte invasion and activation of resident macrophages, resulting in the
formation of granulation tissue [27]. Granulation tissue formation is a wound healing response
in which fibroblasts and endothelial cells recruited by macrophages, invade and proliferate
within the inflamed tissue in an attempt to establish structure and homeostasis at the local
inflammation site [11,27]. Granulation tissue consists of a dense population of macrophages,
fibroblasts, and neovasculature embedded within a loose matrix of fibronectin, collagen, and
hyaluronic acid, serving as an intermediary substrate [31,33]. Fibroblasts are mesenchyme-
derived cells with their primary function being to produce and remodel the local ECM,
providing scaffolding and framework to repair the wound [3]. The persistent presence of
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macrophages within the granulation tissue ensures constant remodeling of the tissue matrix
and constant recruitment of fibroblasts and endothelial cells [27].
The outcome of tissue regeneration or scar formation, i.e. fibrosis, is dependent on the duration
of the chronic response that contributes to cytokine production and formation of granulation
tissue [8]. Fibrosis is the excessive deposition of matrix components that results in destruction
of normal tissue architecture and compromised tissue function and arises from a continuous
injuring stimulus, excessive synthesis or decreased degradation [33]. Synthetic and
degradative functions of fibroblasts are controlled and regulated by signals from the matrix,
as well as leukocyte cytokines and growth factors, wherein macrophages and their phenotype
play an important role [27,52].
4. The foreign body response to biomaterials
The implantation of a biomaterial can intensify the inflammatory response by inducing a
foreign body response (FBR). The FBR at the tissue-material interface is composed of
macrophages and foreign body giant cells (FBGCs) and forms the end-stage response of the
inflammatory and wound healing responses following implantation of a medical device,
prosthesis, or biomaterial [10,29]. Typically, within 2-4 weeks the foreign material is
encapsulated within an almost avascular, fibrous connective tissue, depending on the porosity
of the biomaterial [52]. The FBR is characterized by the presence of macrophages and FBGCs
together with the components of granulation tissue. Macrophages and FBGCs are believed to
exert critical effects on both tissue and implanted material, e.g. degradation, and chemokine
and cytokine production [31].
4.1. Macrophage fusion
Macrophages develop integrins, which play a major role in the adhesion of macrophages to a
biomaterial and in the IL-4-induced macrophage fusion to form FBGCs [10]. Macrophage-
integrin binding to the protein layer on the biomaterial surface provides intracellular signals
that can modulate macrophage behavior, such as cytoskeletal rearrangements and the
formation of adhesion structures, called podosomes. There is extensive interplay between
intracellular signaling molecules activated by integrin binding and cytoskeletal proteins.
Disruption of the adhesion signals promotes anoikis, i.e. apoptosis induced by cell detachment
from its supportive matrix. A hypothesis is that macrophage fusion to form FBGCs is an escape
mechanism to avoid apoptosis [10].
Macrophages adhere to the surface of an implanted biomaterial when they are unable to
phagocytose the material due to a large material-to-cell size ratio. Phagocytosis of large, non-
degradable implanted materials usually does not occur due to the size disparity. When the
particle size in phagocytosis >5 μm, frustrated phagocytosis may occur instead, a process in
which ROIs are secreted aimed to degrade the biomaterial [10,29]. Macrophages fuse with
other macrophages to form multinucleated FBGCs, associated with chronic inflammation
arising from the persistent presence of a foreign body. These multinucleated cells are
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characteristic of granulomatous inflammation and show abundant chromatin with scattered
nuclei in an irregular pattern [31]. The fusion of macrophages to form FBGCs serves to prolong
the life span of these frustrated macrophages, allowing continued release of cytokines and
growth factors [27].
Lymphocytes also seem to play a critical role in the FBR. They have been observed to associate
with adherent macrophages and FBGCs, and enhance macrophage adhesion and fusion, while
the presence of macrophages stimulates lymphocytes to proliferate [31]. Dependent on the
biomaterial, next to macrophages, lymphocytes themselves also produce inflammatory
mediators [10,31]. Lymphocytes enhance adherent macrophage and FBGC activation in terms
of inflammatory cytokine production via paracrine (indirect) and juxtacrine (direct) means
[10]. T cells have been demonstrated to promote macrophage adhesion and fusion via
paracrine effects, however, close association of lymphocytes and macrophages also suggests
direct signaling which has been shown to dominate at later time points of their interaction [11].
4.2. Macrophage phenotype in fusion
The phenotype of the macrophages involved has been shown to play an important role in
biomaterial scaffold remodeling [10,11,52]. The fusion of adherent macrophages to FBGCs is
typically associated with a phenotype switch of the macrophages over time, going from a more
pro-inflammatory activation state (M1) to a more anti-inflammatory activation state (M2). M1
versus M2 macrophage activation has led to morphological variants of multinucleated giant
cells in vitro [10]. The M2 activation cytokines IL-4 and IL-13 promote macrophage fusion and
the formation of large FBGCs with randomly arranged nuclei and high degrees of cytoplasmic
spreading, while the M1 activation cytokine IFN-γ induces more limited degrees of
macrophage fusion with resultant Langerhans-type giant cells. However, the activation state
of fusing macrophages is neither M1-like, nor M2-like but rather an in-between state in the
continuous spectrum of macrophage polarization. This suggests that biomaterial activation is
unique in the process of inflammation [10,11].
The fusion of M2-activated macrophages into FBGCs is stimulated by IL-4 and IL-13, assumed
to be secreted by activated T cells [11]. The precise origins of FBGC-inducing cytokines at the
implant site remain unclear, with TH2 cells, NK cells, eosinophils, basophils, and mast cells as
possible candidates [31]. Both IL-4 and IL-13 were found to up-regulate mannose receptors on
fusing macrophages, which mediate endo- and phagocytosis, with localization of the receptor
at the fusion interface [10]. MCP-1 is also involved in FBGC formation though not by recruiting
cells but rather by guiding macrophage chemotaxis toward each other [10,11].
Biomaterial-adherent macrophages and FBGCs seem to show combined action of biomaterial
degradation and down-modulation of pro-inflammatory mediators. Perhaps the presence of
macrophage fusion and FBGC formation on biomaterial surfaces represents host down-
modulation of pro-inflammatory cytokine production, possibly via phagocytic removal of
macrophages actively releasing these cytokines [31]. Next to promoting M2 phenotype and
macrophage fusion, IL-4 prevents apoptosis of biomaterial-adherent macrophages by
inducing shedding of TNF-α receptor I, preventing this TNF-α-mediated process [11].
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4.3. Biomaterial degradation and fibrosis
Macrophages and FBGCs mediate biomaterial degradation by concentrating phagocytic and
oxidative activities at the interface between the cell and the biomaterial. During frustrated
phagocytosis, macrophages and FBGCs release degradative mediators such as ROIs,
degradative enzymes, and acid into the privileged zone between the cell membrane and the
biomaterial surface such that immediate buffering or inhibition of these mediators is delayed
or reduced [10]. In this process the phagocytic activity of macrophages decreases, while their
degradative capacity increases [11].
FBGCs have the potential to be responsive to cellular signals via cell surface receptor
expression as well as actively participate in the inflammatory response through the production
of cytokines [10]. They produce anti-inflammatory cytokines, e.g. IL-10, which may be counter-
regulated by the proteolytic and pro-oxidant microenvironment. Additionally, FBGCs are
thought to release pro-fibrotic factors, e.g. TGF-β and PDGF, which trigger the action of
fibroblasts and endothelial cells. Continuous action of FBGCs is assumed to result in prolonged
fibroblast activation and excessive biomaterial-associated matrix deposition, leading to
impaired wound healing and excessive fibrosis [11]. Therefore, FBGC formation has appeared
to be an undesirable phenomenon with a negative impact on biocompatibility, producing
cytokines that bias wound healing cells toward a fibrogenic phenotype [31]. Efforts in the
design of the biomaterial for in situ tissue engineering of heart valves should enhance the
biocompatibility, limiting macrophage fusion into FBGCs. Surface chemistry-dependent
modulation of the protein layer may enable different receptor binding and signaling in the
immune cells leading to altered cellular responses, promoting wound healing while sustaining
implant function [11].
5. Modulating the immune response
The implantation of any biomaterial initiates an immune response. However, the extent and
severity of this response can be modulated by adapting scaffold properties. As described in
the previous sections, the immune response is a multi-phased cascade involving many
different components. The combined effect of these components will determine the end-stage
outcome of the immune response, ranging from pathological fibrotic repair to fully functional
regeneration of the original tissue. By interfering with specific elements within this
inflammatory cascade, the downstream outcome can be drastically affected, for better or for
worse. In this plane of intersection, immuno-modulating scaffolds for in situ tissue engineered
heart valves are being developed. The development of such a ‘smart’ scaffold bridges multiple
length-scales and is dependent on a multitude of scaffold features. Biological scaffolds
inherently come with a natural architecture and a cocktail of signaling components, which
would be difficult to replicate with a synthetic counterpart. Synthetic scaffolds, on the other
hand, offer a more dedicated control of individual elements in comparison to biological
scaffolds. Either scaffold type can be modified within its own framework. There is a legion of
possibilities to modify scaffolds over various interdependent scales, ranging from tuning
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biomaterial surface chemistry, scaffold architecture and mechanical properties, to the
incorporation of bioactives and targeting of specific cell types. Apart from the scaffold itself,
the implantation procedure contributes to the immune response. The method of implantation
affects the degree of inflammation [27], and as such should be taken into account in scaffold
design.
5.1. Biomaterial surface engineering
Biocompatibility and thrombogeneity are particularly important during the onset of the
immune response. Immediately after implantation, blood proteins precipitate onto the
biomaterial surface, creating an inflammatory milieu that determines the activation of the
complement and coagulation cascades. Biomaterial surface chemistry influences the proteins
that adsorb, which mediates subsequent interactions with immune cells and may lead to their
activation [8]. Factors that affect the amount, composition, and conformation of proteins within
the initial layer include the hydrophobicity/hydrophilicity of a surface, as well as its charge
and the distribution of charged groups [32]. Incorporation of anti-fouling properties into the
biomaterial surface has proven an efficient method to block non-specific protein binding and
promote specific biomolecule-binding. This is typically achieved by modifications with
hydrophilic polymers, such as poly(ethylene glycol) (PEG), that act as molecular spacers and
create a hydrophilic microenvironment that can resist non-specific protein adsorption and cell
binding [53].
Biomaterial surface topography and micron-scale architecture can modulate the cell-scaffold
interactions that influence immune cell activation, alignment, infiltration, and fusion.
Variations in surface roughness and topography affect cell adhesion, morphology, and
cytokine secretion. The cell-surface interaction can change quantity and identity of secreted
pro-inflammatory cytokines and chemokines, the gene expression pattern, and downstream
remodeling events [11,47]. For example, one of the key cellular immune response mechanisms
which can be targeted for control of biocompatibility is the mechanism for macrophage
adhesion [31,54]. Macrophage fusion on biomaterial surfaces is material dependent, indicating
that the surface must have an appropriate array of adsorbed proteins in order for adherent
cells to adopt the necessary phenotype to fuse into FBGCs [10]. Furthermore, surface roughness
of electrospun fibers has been shown to affect blood activation [55], illustrating the importance
of appropriate surface engineering, in particular in the early phases of inflammation.
5.2. Scaffold architecture
Cell infiltration into the scaffold is one of the prerequisites for succesful tissue regeneration. It
was shown that early infiltration of immune cells determines the degree of downstream ECM
production and remodeling [56]. Cell infiltration is primarily determined by the scaffold
architecture, or microstructure. Decellularized homograft/xenograft valves have shown
limited cell infiltration, resulting in poor tissue remodeling and even degeneration. In contrast,
decellularized in vitro tissue-engineered valves have shown fast repopulation with host cells
and tissue remodeling following a distinct demarcation line. It has been suggested that this
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critical difference in cell infiltration is due to a lack of the dense, native-like microstructural
arrangement in tissue-engineered valves, as opposed to native valves [57].
For synthetic scaffolds, the importance of scaffold architecture is even more evident. In contrast
to natural ECM, cells are typically unable to rapidly break down synthetic biomaterials in order
to migrate. Therefore, cell infiltration into a synthetic scaffold is generally dependent on the
available pore size, or void space [58,59]. Apart from overall cell infiltration, the pore size can
also affect cell phenotype. For example, pore size has shown to be an important factor in the
degree of macrophage fusion and material encapsulation. Porous implants with uniform
spherical pores of 30-40 μm were shown to elicit healing with minimal fibrosis, high
vascularity, and a higher M2/M1 macrophage ratio [52]. It has to be noted however, that the
optimal pore size is not generic and has to be tailored to the application.
Synthetic scaffolds for heart valve tissue engineering typically consist of nano- or microfibers,
with a high surface area-to-volume ratio. This fibrous architecture dictates the behavior of
infiltrating cells. In addition to the void space, the fiber diameter and inter-fiber distance
determine cell adhesion, spreading and proliferation [60,61]. Fiber diameter has also shown
to affect platelet adhesion and coagulation activation [55]. Fiber alignment guides cell
orientation and migration via contact guidance. Furthermore, it was shown that fiber
alignment enhanced cell infiltration into a nanofibrous PLLA scaffold [62]. Novel processing
techniques to produce fibrous 3D scaffolds with adjustable void space and/or aligned fibers
(e.g. low-temperature electrospinning [63]), enhance the degrees of freedom in scaffold
modification via 3D architecture (figure 4). For complex structures, such as the aortic valve,
multi-layered scaffolds might be required to achieve suitable local cues [59,64].
Figure 4. (A) Photograph of an electrospun poly(ε-caprolactone) heart valve demonstrating 3D valve architecture, and
scanning electron micrographs of its microstructure showing either random (B) or aligned microfibers (C) (scalebar =
100 µm; images courtesy of M. Simonet and G. Argento).
5.3. Mechanical properties and degradation rate
Heart valve scaffolds require appropriate mechanical properties to endure the cyclic stresses
and strains exerted by the hemodynamic environment. However, next to proper functioning
in the hemodynamic environment, scaffold mechanical properties play an important role on
the cellular level. The macromechanical properties are determined by the intrinsic material
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properties, the scaffold architecture and the degradation rate. The intrinsic material properties
(e.g. stiffness) and the scaffold architecture (e.g. anisotropy) determine the local stresses and
strains experienced by the cell. It is well recognized that mechanical conditioning is an
important stimulus for ECM production and remodeling. It has been hypothesized that
polymeric scaffolds can divert loads from the cells, so-called ’cell shielding‘, resulting in
hampered ECM production. Furthermore, the scaffold or matrix stiffness can modulate the
differentiation of cells into pathological phenotypes, e.g. osteoblastic or myofibroblastic, in
response to mechanical and biochemical cues [5]. Therefore, efficient transduction of loads
from the biomaterial to the cells is crucial. Elastomers typically exhibit adequate mechano‐
transduction properties, making them a favorable class of materials for application as synthetic
scaffolds [25].
Mechanical integrity of the scaffold is dependent on the degradation rate of the material, or
rather on the balance between material degradation and ECM production. Accelerated
material degradation can result in mechanical instability and valve failure. On the other hand,
long-term presence of the biomaterial results in prolonged macrophage activity. Macrophages
typically persist at the implantation site until the biomaterial is completely resorbed. When
uncontrolled, this may lead to excessive chronic inflammation resulting in fibrosis,
calcification, and/or degeneration. Mineralization of synthetic or biologic scaffolds is end-stage
pathology, generally irreversible and untreatable. This underlines the importance of timely
degradation of the biomaterial. Apart from proper material selection, degradation rate of
polymers is tunable by varying copolymer ratios [3]. Variations in degradation kinetics of
materials are also employed for controlled delivery of bioactives, for example by introducing
fast-degrading fibrin gel [65] or synthetic or biological microspheres [23,66] into the scaffold.
5.4. Incorporation of bioactives
Throughout the course of the immune response, signaling factors orchestrate the actions of the
immune cells. By incorporating bioactive factors into the biomaterial scaffold, the cellular niche
can be modulated locally. These biochemical factors can direct local cellular function, or
promote recruitment of specific cell types via chemotaxis. Additionally, the crosstalk between
immune cells and tissue cells can be enhanced, regulating the healing process [11]. Since these
signaling factors play a role in a specific phase of the immune response, spatio-temporal control
of growth factor or cytokine release has been the aim for many tissue engineering scaffolds.
For example, long-term release of stromal cell-derived factor 1α (SDF-1α) from porous PLGA
scaffolds has demonstrated to result in reduced numbers and degranulation of mast cells at
the scaffold in a subcutaneous mouse model. This led to downstream alterations in the
inflammatory cascade, jumpstarting regeneration with enhanced participation of progenitor
cells, increased angiogenesis and decreased fibrosis [67]. De Visscher et al. developed heart
valves constructed from photo-oxidized bovine pericardium, which were impregnated with
SDF-1α in combination with fibronectin to improve the SDF-1α presentation to the cells.
Implanted in the pulmonary position in sheep, these valves demonstrated improved homing
of primitive cells and normal functioning at 5 months follow-up [68]. Other pro-angiogenic
factors, such as VEGF, have shown to play a similar role in vascularization and endotheliali‐
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zation via recruitment of bone marrow-derived circulating cells, with an essential paracrine
role for myeloid cells [69]. Injectable hydrogels featuring a sustained release of VEGF, either
or not combined with PDGF, have shown to enhance angiogenesis [70,71]. Dual delivery of
MCP-1 and VEGF was applied to promote early monocyte invasion as well as angiogenesis.
This was shown to increase mature vessel formation via enhanced endothelial and smooth
muscle cell recruitment and displayed a trend of macrophage polarization to the M2 type in a
time- and dose-dependent manner [66]. MCP-1 has demonstrated to be a potent immune-
modulatory factor, leading to successful remodeling and regeneration of a PCL/PLLA blood
vessel graft in mice [23]. Decellularized porcine aortic valves coated with a fusion protein of
fibronectin and hepatocyte growth factor (HGF) demonstrated modest acceleration of
infiltration of tissue cells, particularly in the valve leaflet, after implantation in a dog model
[72].
Single extracellular molecules can impact both pro-inflammatory and anti-inflammatory
pathways in different cell types participating in the repair response [35]. The shift from pro-
inflammatory to anti-inflammatory response is generally mediated by lipoxins, protectins, and
resolvins, actively promoting resolution of infection and tissue repair. Lipoxins are arachidonic
acid (AA) derivatives generated by lipoxygenases, and stop the influx of neutrophils, promote
the uptake of apoptotic neutrophils by macrophages and recruit additional monocytes to help
clear away dead cells and tissue debris [28,39]. Incorporation of such bioactive components
may enhance the resolution of the inflammatory response, avoiding uncontrolled chronic
inflammation. Resolution of inflammation is also mediated by glucocorticoids, which inhibit
inflammatory cell activation by withdrawing the synthesis of inflammatory mediators, and
promote resolution of inflammation by enhancing anti-inflammatory cytokine release [29,54].
Glucocorticoids have been shown to modulate the phenotype of infiltrating macrophages and
lymphocytes and could thus be used locally to regulate the cellular response [54].
An alternative to incorporating specific signaling moieties into a scaffold is to preseed the
scaffold with cells that act as natural signaling factories. Cells, typically bone marrow-derived
mononuclear cells, harvested from the host are directly seeded into a scaffold, which is
subsequently implanted in a single operation. Although the preseeded cells are cleared from
the scaffold within several days after implantation, they mediate the immune response via
paracrine signaling by secreting a natural cocktail of growth factors and cytokines. This
approach has shown prosperous results in clinical trials using synthetic blood vessel grafts
[24]. Furthermore, a similar approach using decellularized tissue-engineered heart valves has
shown promising short-term results after 4 week implantation in the pulmonary position in
non-human primates [73].
Apart from boosting selected signaling molecules, biomaterials can be designed to tether
endogenously released factors to promote a regenerative microenvironment. Natural
occurring GAGs have been identified to bind and modify inflammatory factors like
interleukins and chemokines, e.g. IL-10 [11]. Subtle differences in GAG structure and/or
sequence might be sensed by signaling molecules, guiding their interaction with the ECM and
mediating their presentation to leukocytes [11]. In this way, physiological cytokine
concentrations are ensured, reducing the risk of adverse side-effects. Heparan sulfate is well-
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recognized as a natural binding site for many growth factors and cytokines, a feature which
has been exploited by developing heparin-mimetic peptide nanofibers that are capable of
binding growth factors such as VEGF and HGF [74].
Clearly, the use of bioactives or on-the-fly harvestable cells is a powerful tool to create immune-
modulating scaffolds. Methods using covalent immobilization of factors [65], microspheres
with controlled degradation profiles [66] or hollow-fiber electrospinning techniques [59]
enable optimized spatio-temporal control of one or multiple factors. Furthermore, advanced
hydrogels have been developed to offer on-demand, remote-controlled release using a
magnetic field [75]. With state-of-the-art supramolecular polymers it is possible to engineer
cell-responsive substrates [76], offering truly ‘smart’ scaffolds that can interact with their
environment to mediate the host response to the biomaterial.
5.5. Cell recruitment and differentiation
The inflammatory response is mainly driven by colonization of the scaffold by blood-derived
cells. The nature of the infiltrating cells and their differentiation were demonstrated of pivotal
importance to control the delicate balance between fibrotic or functional regenerated ECM
production. Of all the cells involved in the immune response, several cell populations can be
identified as target cells for in situ heart valve tissue engineering.
Macrophages are the predominant mediators throughout the entire immune response, making
them an attractive therapeutic target [77]. Although, the precise nature of macrophage
plasticity and polarization has yet to be illuminated, it has been shown that early macrophage
phenotype determines the end-stage outcome in various biological matrices. In particular, an
increased ratio of M2/M1 macrophages correlates to enhanced remodeling, which is likely
mediated by differential attraction of secondary cells [78]. By promoting the M2 phenotype,
either via specific recruitment or local polarization, the inflammatory response may instantly
be directed towards healing instead of inflammation [48,52]. With the identification of multiple
subtypes, it is likely that the various macrophage phenotypes play a critical role throughout
the various stages of acute inflammation, the healing phase and the resolution of inflammation
(figure 5).
ECM production and remodeling is governed by the attraction of secondary cells to the
scaffold,  consisting of  mature  (myo-)fibroblasts  and endothelial  cells,  as  well  as  various
stem/progenitor cells, released into the circulation by the bone marrow. Furthermore, it has
been suggested that adult valve interstitial cells are continuously replenished via circulat‐
ing  endothelial  or  mesenchymal  cell  precursors  derived  from  the  bone  marrow  and
subsequently  undergo  endothelial-to-mesenchymal-transition  (EndoMT)  [5].  Circulating
progenitors, such as endothelial progenitor cells (EPC), can have a significant influence on
the inflammatory response [4,12,79]. EPC are hypothesized to be an important target cell
for endothelialization. Rapid formation of an endothelium over a scaffold is desirable as it
acts  as  a  dynamic  and  selective  barrier  by  maintaining  a  nonthrombogenic  surface,
controlling the transfer of molecules across the layer, and regulating immune and inflamma‐
tory reactions. The endothelial layer also interacts with underlying cells to regulate their
growth and proliferation [12].
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Figure 5. Hypothesized role of the various macrophage polarization states throughout the process of inflammation
and tissue regeneration in response to scaffold implantation. Illustration by Anthal Smits.
Mesenchymal stem cells (MSCs) proliferate during the healing phase, directed by cytokines
secreted by nearby cells, e.g. activated platelets and macrophages, and by ECM components
such as collagen peptides and fibronectin [29]. MSCs produce an immunoprivileged
environment by preventing the activation and proliferation of DCs, T cells, macrophages, and
PMNs through direct cell-cell interactions and paracrine signaling [8]. Cells derived from
immunoprivileged regions have been delivered to promote cell engraftment and protect grafts
against autoimmune and allogeneic rejection. These cells secrete a range of factors, eg. TGF-
β and IL-10, inducing regulatory T-cell differentiation/expansion, which enhances immuno‐
protection [8].
Recruitment and adhesion of target cell types can be achieved by offering binding domains on
the scaffold, for example using supramolecular building blocks with cell-specific peptide
sequences [76,79]. When combined with anti-fouling materials, such as PEG, this results in
highly selective substrates.
5.6. Minimally invasive implantation methods
Independent of the biomaterial, the injury incurred during the implantation process will
trigger an immune response, due to the disruption of host tissue and induction of cell damage.
Besides substantial mortality and morbidity risks, invasive open heart surgery for heart valve
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replacement causes extensive tissue damage, giving rise to DAMPs, which prime the system
for an enhanced immune response [29]. As an alternative, various transvascular, catheter-
based techniques, as well as alternative minimally invasive surgical techniques, such as the
transapical approach, have been developed [4,80,81]. This has implication for the scaffold
design as the scaffold must be crimped and incorporated into a stent. Upon delivery at the
valve annulus, the scaffold must also be able to expand properly, be held in place and instantly
function within the hemodynamic environment. Transapical valve implantation of preseeded
decellularized tissue engineered heart valves into both the aortic and pulmonary position has
already proven feasible in pre-clinical models [82,83].
6. Challenges and pitfalls
In situ tissue engineering of heart valves represents a quick, cheap, and on-demand approach.
Immunomodulatory scaffolds hold great promise for future application and commercializa‐
tion. However, some priority challenges remain to be addressed in the translation from bench
to bed.
6.1. ECM formation versus fibrosis
One of the main challenges for in situ tissue engineering is to stimulate functional ECM
formation without inducing fibrosis. To maintain functionality of the valve, rapid ECM
formation is required in order to overtake the load-bearing role of the degrading scaffold.
However, cells and molecules that are stimulatory for ECM production have been designated
as pro-fibrotic mediators. This poses a paradoxal challenge. Macrophage plasticity is a striking
example. M2 macrophages have been identified as pro-wound healing cells, promoting ECM
production by secretion of IL-4 and TGF-β. On the other hand, both IL-4 and TGF-β are strong
inducers of fibrosis if not tightly regulated. Chemokines, such as MCP-1, have been identified
as pro-fibrotic mediators by attracting fibrocytes and stimulation of M2 polarization [84,85].
On the other hand, MCP-1 inhibition leads to delayed or inhibited wound healing [86].
Fibrocytes are blood-borne mesenchymal stem cell progenitors with a fibroblast/myofibro‐
blast-like phenotype (CD34+/CD45+/collagen type I+) that similarly have been related to both
ECM formation and fibrosis. The same holds for EndoMT-derived (myo-)fibroblasts.
However, the local activation state of recruited myofibroblasts, rather than the source,
determines their ECM remodeling activity. For example, TLR-signaling promotes fibroblasts
to differentiate into collagen-producing myofibroblasts [84]. Valvular interstitial cells (VICs)
in the adult valve have a quiescent myofibroblast-like phenotype. Regulating the activation
state of colonizing myofibroblasts in the scaffold is pivotal in the prevention of fibrosis and
obtaining a VIC-like population. The TGF-β pathway is one of the main players in this process.
Furthermore, IL-10 has been shown to inhibit fibrosis in numerous animal models [84],
underlining that timely resolution of inflammation is one of the main challenges for in situ
tissue engineering.




In cardiovascular in situ tissue regeneration, the hemodynamic environment plays a key role
by directing cell recruitment and cell differentiation. The mechanical load applied to the heart
valves is a powerful regulator of cell phenotype, influencing many cell functions such as
orientation, replication, growth factor production, and collagen synthesis [33]. In cardiovas‐
cular devices, apoptosis is often induced by shear stress arising from the blood flow [10]. Shear
stress also has a significant effect on adhesion of circulating cells to the valve scaffold. Direct
intimal binding of cells to the ventricular side of the leaflet is unlikely due to high shear forces
during systole. In contrast, end-systolic and diastolic turbulations on the aortic side of the
leaflet typically result in low shear stresses that allow for cell adhesion to the scaffold [4].
So far, the exact mechanism behind cell population of heart valve replacements with host cells
remains elusive. For blood vessels, animal studies have identified trans-anastomotic ingrowth
as the main source of host tissue cells in the scaffold [87]. However, this is most likely an animal
model-dependent phenomenon, as it is known that trans-anastomotic ingrowth is very limited
in humans [88]. Therefore, the use of humanized animal models or in vitro model systems [89]
is indispensible in evaluating scaffold performance for future clinical applications.
6.3. Comorbidity and impaired wound healing
Little is known about the effect of the pathological status of a tissue, organ, or patient on the
fate of a tissue engineered heart valve. It is reasonable to believe that the pre-existing pathology
or existing risk factors would influence wound healing and long-term outcomes of valve
implantation. One of the most complicated aspects of designing a replacement scaffold for
diseased tissue would be the incorporation of measures which prevent the device from
succumbing to the same fate as the diseased tissue it is replacing [12].
Impaired wound healing conditions include advanced age, diabetes mellitus (insulin
resistance), vascular diseases (e.g. atherosclerosis), and obesity, in which adipose tissue
functions as initiator of the chronic inflammatory response. Diabetic patients have significantly
impaired wound healing as they are relatively immunocompromised and have higher blood
glucose levels affecting leukocyte function [90]. Diabetes and advanced age are associated with
delayed or impaired wound healing through a reduced ability to transition from an M1 to an
M2 macrophage phenotype [52]. Malnutrition adversely affects wound healing by prolonging
inflammation, inhibiting fibroblast function, and reducing angiogenesis and collagen
deposition. For example, carbohydrates are needed for collagen synthesis, and ω-3-fatty acids
are needed for modulation of the arachidonic acid pathway, resolving inflammation [90].
The patient’s regenerative potential is dependent on age. The concentration of progenitor cells
in human blood decreases with age [4]. Furthermore, aging typically leads to impaired
angiogenesis and local immunity is altered due to lack of growth factors, increased neutrophil
invasion and higher number of mature macrophages. Levels of TGF-β in wounds of elderly
are, like fetal, markedly reduced, which is possibly related to reduced scarring with age [35].
Next to regeneration potential, the rate at which the scaffold degrades may also be age-specific
due to variations in cell availability.
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Any chronic disease which affects the cardio-respiratory system may adversely affect the
supply of oxygen and other nutrients required for wound healing. Although hypoxia is one
of the chemoattractants for neutrophils and macrophages, oxygen is needed for their optimal
function and to allow phagocytosis. Oxygen is also essential for collagen deposition as it acts
as a substrate in the hydroxylation of proline and lysine residues. Smoking affects oxygen
partial pressures and causes more wound healing complications and it is likely that smoking
may also affect immune function and collagen deposition [90].
The use of diseased cells or tissues in humanized animal models or in vitro model systems [89]
may aid in gaining insight in the effects of comorbidities on valve regeneration.
6.4. Patient heterogeneity
In vivo remodeling of tissue engineered heart valves displays considerable variability among
patients, owing to biological heterogeneity among individuals in physiological tissue
remodeling potential [5]. This heterogeneity could be a result of mutations or polymorphisms
in key proteins central to ECM synthesis and remodeling [2]. The goal is to understand and
potentially control human variation in different facets of biomaterial-tissue interaction and the
healing process by developing robust or even patient-tailored scaffolds.
To cope with patient-to-patient heterogeneity, an important issue in tissue engineering of
aortic heart valves will be the real-time noninvasive and non-destructive assessment of
mechanical properties both in vitro and in vivo to ensure tissue quality and function [5]. The
challenge here is to find appropriate methodologies to evaluate the evolving structural
remodeling and functionality, especially in a noninvasive manner so that the valve can be
followed over time [5]. One way of approaching this issue is developing imaging modalities
and discovering new biomarkers of inflammation which would help further understanding
of inflammatory diseases and discerning events related to inflammation in heart valve tissue-
engineered implants [12]. When applied to engineered heart valves, developed biomarkers
should correlate directly with success and failure in order to generate outcome measurements,
such as laboratory assays or imaging results that substitute for and reflect the mechanism of
a significant clinical event or characteristic, e.g. stenosis, calcification, or infection [5]. An
important consideration is whether calcification, the major pathologic process in valve
degeneration, will be problematic. Evidence suggests that calcification may not be a major
problem as long as the scaffold is ultimately resorbed and/or not intrinsically mineralizable,
the interstitial cells are viable, and the ECM is capable of remodeling [5].
For the translation from bench to bed, there must be understanding of the mechanisms
involved and development of biomarkers, assays and tools for the assessment of valve
regeneration. Surrogate and true endpoints must be defined to characterize and assure the
quality of the tissue constructs, and predict outcomes as early as possible [5]. Key targets for
characterizing tissue-engineered constructs include tissue composition, cellular gene
expression and phenotype, ECM, and other key effectors of tissue remodeling and tissue
quality [5].




The complexity of the immune response poses a challenging environment for in situ tissue
engineering of heart valves [46]. Clearly, a better understanding of the underlying pathways
appears crucial for controlling the fate of implanted biomaterial scaffolds and modulating
inflammatory reactions in such a way as to induce tissue regeneration and remodeling and
prevent fibrosis and/or degeneration [12]. Remaining largely unknown are the specifications
of the optimal components (i.e. cells, scaffold and potentially biological modulators) and
process conditions (mechanical and metabolic) that will facilitate the formation of optimal
substitute heart valve tissues, whose function best emulates the structure, function, and
extended durability of a natural valve in vivo [5]. However, the prosperous results of synthetic
and biological scaffolds so far demonstrate the ground-breaking potential of in situ tissue
engineering for heart valves.
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